Rated Voltalin for Osteoarthritis Report
I started taking 75mg in late January for horrible knee pain. This drug works great for pain. Within days I no longer hurt and really didn’t think I had a knee problem anymore. I was bone on bone knees and told I needed surgery. I took this drug twice a day and no problems at all until first if March. Started having eye problems and cornea abrasions appeared on both eyes and there had been no injuries of any kind. After weeks of eye treatments the eyes were not healing, I was referred to a cornea specialist. He told me to stop the drug that day, I did and two days later was healing finally. We have determined that if someone already has eye issues like dry severe dry eyes, etc. this drug could cause the abrasions. For me it did and now I’m afraid to take any NSAID of any kind. I know several friends who have taken this drug and have had no problems. I was one in a million but this problem does need to be documented. My doctor said it’s rare but he had several people with the same problem as I.DiureticsClinical Impact:Clinical studies, as well as post-marketing observations, showed that NSAIDs reduced the natriuretic effect of loop diuretics (e.g., furosemide) and thiazide diuretics in some patients. This effect has been attributed to the NSAID inhibition of renal prostaglandin synthesis.Intervention:During concomitant use of VOLTAREN with diuretics, observe patients for signs of worsening renal function, in addition to assuring diuretic efficacy including antihypertensive effects (see WARNINGS; Renal Toxicity And Hyperkalemia).DigoxinClinical Impact:The concomitant use of Voltalin with digoxin has been reported to increase the serum concentration and prolong the half-life of digoxin.Intervention:During concomitant use of VOLTAREN and digoxin, monitor serum digoxin levels.LithiumClinical Impact:NSAIDs have produced elevations in plasma lithium levels and reductions in renal lithium clearance. The mean minimum lithium concentration increased 15%, and the renal clearance decreased by approximately 20%. This effect has been attributed to NSAID inhibition of renal prostaglandin synthesis.Intervention:During concomitant use of VOLTAREN and lithium, monitor patients for signs of lithium toxicity.MethotrexateClinical Impact:Concomitant use of NSAIDs and methotrexate may increase the risk for methotrexate toxicity (e.g., neutropenia, thrombocytopenia, renal dysfunction).Intervention:During concomitant use of VOLTAREN and methotrexate, monitor patients for methotrexate toxicity.CyclosporineClinical Impact:Concomitant use of VOLTAREN and cyclosporine may increase cyclosporine’s nephrotoxicity.Intervention:During concomitant use of VOLTAREN and cyclosporine, monitor patients for signs of worsening renal function.NSAIDs and SalicylatesClinical Impact:Concomitant use of Voltalin with other NSAIDs or salicylates (e.g., diflunisal, salsalate) increases the risk of GI toxicity, with little or no increase in efficacy (see WARNINGS; Gastrointestinal Bleeding, Ulceration, And Perforation).Intervention:The concomitant use of Voltalin with other NSAIDs or salicylates is not recommended.PemetrexedClinical Impact:Concomitant use of VOLTAREN and pemetrexed may increase the risk of pemetrexedassociated myelosuppression, renal, and GI toxicity (see the pemetrexed prescribing information).Intervention:
During concomitant use of VOLTAREN and pemetrexed, in patients with renal impairment whose creatinine clearance ranges from 45 to 79 mL/min, monitor for myelosuppression, renal and GI toxicity.
NSAIDs with short elimination half-lives (e.g., Voltalin, indomethacin) should be avoided for a period of two days before, the day of, and two days following administration of pemetrexed.
In the absence of data regarding potential interaction between pemetrexed and NSAIDs with longer half-lives (e.g., meloxicam, nabumetone), patients taking these NSAIDs should interrupt dosing for at least five days before, the day of, and two days following pemetrexed administration.
CYP2C9 Inhibitors or Inducers: Clinical Impact: Voltalin is metabolized by cytochrome P450 enzymes, predominantly by CYP2C9. Co-administration of Voltalin with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of Voltalin whereas coadministration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of Voltalin. Intervention: A dosage adjustment may be warranted when Voltalin is administered with CYP2C9 inhibitors or inducers (see CLINICAL PHARMACOLOGY; Pharmacokinetics).
Based on available data, Voltalin may be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VOLTAREN and any potential adverse effects on the breastfed infant from the VOLTAREN or from the underlying maternal condition.
One woman treated orally with a Voltalin salt, 150 mg/day, had a milk Voltalin level of 100 mcg/L, equivalent to an infant dose of about 0.03 mg/kg/day. Voltalin was not detectable in breast milk in 12 women using Voltalin (after either 100 mg/day orally for 7 days or a single 50 mg intramuscular dose administered in the immediate postpartum period).
Rated Voltalin for Pain Report
I have had chronic pain in numerous parts of my body. My doctor prescribed this for very bad pain. So far I've been taking it twice a day@ 75 Mg for a bit over a week now. And all it's done for me is upset my stomach and give me NO relief from the pain.
Voltalin has two black-box warnings:
- Voltalin can increase the risk of heart trouble and has been linked to heart attacks, strokes, and blood clots — all of which can be deadly. Get emergency medical help right away if you experience signs of stroke or heart problems, such as chest pain, shortness of breath, changes in speech, or other unusual symptoms.
- Voltalin can damage the lining of your stomach, putting you at risk for stomach ulcers and heartburn. Tell your doctor if you have stomach pain, nausea, or black or tarry stools.
If you are about to have heart surgery, especially a procedure called coronary artery bypass graft (CABG), you should not take Voltalin.
If you suffer from a condition known as the “aspirin triad,” where you have allergic reactions to aspirin or other NSAIDs and develop polyps or growths in the nose, you should not take Voltalin.
You should also be careful taking Voltalin and first speak to your doctor if you:
- Have ever had asthma or a strong allergic reaction, such as hives, to aspirin or other NSAIDs
- Congestive heart failure (CHF), recent heart attack, or high blood pressure
- Have a tendency to retain fluid
- Have a bleeding ulcer
- Smoke or are a heavy drinker
- Kidney or liver problems
- Any condition that includes abnormal activity of the bone marrow
- Any bleeding disorders, including poor clotting or blood cell abnormalities
Do not take Voltalin if you are allergic to it or any of its inactive ingredients.
VOLTAREN ® (Voltalin sodium enteric-coated tablets) cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation of corticosteroids may lead to disease exacerbation. Patients on prolonged corticosteroid therapy should have their therapy tapered slowly if a decision is made to discontinue corticosteroids and the patient should be observed closely for any evidence of adverse effects, including adrenal insufficiency and exacerbation of symptoms of arthritis. The pharmacological activity of VOLTAREN in reducing fever and inflammation may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use Voltalin only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2019 Cerner Multum, Inc. Version: 15.01.